Zhejiang East-Asia Pharmaceutical (SH:605177)2025-02-10 07:45Financial Performance Expectations - Zhejiang Dongya Pharmaceutical Co., Ltd. expects a net loss attributable to shareholders of between -95 million to -115 million yuan for the fiscal year 2024[1]. - The company anticipates a net profit loss excluding non-recurring items between -90 million to -110 million yuan for 2024[1]. Revenue and Profitability Challenges - The decrease in gross profit is estimated to be around 30 million yuan year-on-year due to intensified competition in the intermediate and raw material drug industry and changes in major customers' operating conditions[2]. Research and Development Investments - Research and development expenses are projected to increase by approximately 30 million yuan year-on-year as the company continues to invest in integrated development of raw materials and formulations[2]. Inventory and Asset Impairments - The company plans to recognize inventory impairment provisions of about 130 million yuan due to expected net realizable value of certain inventories being lower than their cost[2]. - An asset impairment provision of around 11 million yuan is expected for fixed assets with recoverable amounts below their book values[2]. - Estimated losses of approximately 19 million yuan are anticipated from the disposal of dismantled, eliminated, and scrapped equipment[2]. Credit Rating - The company's credit rating remains at AA- with a stable outlook, as per the latest assessment by Dongfang Jincheng[1].